Glycogen Synthase Kinase-3 beta: Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals

Imagem de Miniatura
Arquivos
art_MUNKHOLM_Glycogen_Synthase_Kinase3_beta_Variation_over_Time_and_2016.PDF (145.48 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
MUNKHOLM, Klaus
LENSKJOLD, Toke
JACOBY, Anne Sophie
MISKOWIAK, Kamilla Woznica
VINBERG, Maj
JOAQUIM, Helena Giroud Passarelli
KESSING, Lars Vedel
Citação
NEUROPSYCHOBIOLOGY, v.73, n.2, p.108-115, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Evidence indicates a role for glycogen synthase kinase-3 beta (GSK-3 beta) in the pathophysiology of mood disorders and in cognitive disturbances; however, the natural variation in GSK-3 beta activity over time is unknown. We aimed to investigate GSK-3 beta activity over time and its possible correlation with emotional lability, subjective mood fluctuations and cognitive function in healthy individuals. Thirty-seven healthy subjects were evaluated with neuropsychological tests and blood samples at baseline and 12-week follow-up. Total GSK-3 beta and serine-9-phosphorylated GSK-3 beta in peripheral blood mononuclear cells were quantitated using enzyme immunometric assays. The activity of GSK-3 beta (serine-9-phosphorylated GSK-3 beta/total GSK-3 beta) was lower at baseline compared with follow-up. No significant mean change over time was observed in levels of total GSK-3 beta and serine-9-phosphorylated GSK-3 beta. Exploratory analysis revealed lower activity of GSK-3 beta in spring and summer compared with the fall season. No correlation was observed between GSK-3 beta activity and emotional lability, subjective mood fluctuations or cognitive function. The results suggest that intra- and interindividual variation in GSK-3 beta activity over time could contribute to the heterogeneity of findings in clinical studies. The stability of GSK-3 beta activity and the role of potential moderators of GSK-3 beta activity warrant further investigation. Clinical studies of GSK-3 beta should consider including repeated measures of both cases and healthy individuals. (C) 2016 S. Karger AG, Basel
Palavras-chave
Bipolar disorder, Peripheral blood, Biomarker
URI
https://observatorio.fm.usp.br/handle/OPI/14365
Referências
  1. Atsma F, 2011, TRANSFUSION, V51, P1883, DOI 10.1111/j.1537-2995.2011.03270.x
  2. Castri P, 2007, EUR J NEUROSCI, V26, P2469, DOI 10.1111/j.1460-9568.2007.05869.x
  3. Geddes JR, 2010, LANCET, V375, P385, DOI 10.1016/S0140-6736(09)61828-6
  4. Kessing LV, 2010, BIPOLAR DISORD, V12, P87, DOI 10.1111/j.1399-5618.2009.00788.x
  5. Munkholm K, 2015, BIPOLAR DISORD, V17, P257, DOI 10.1111/bdi.12245
  6. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  7. Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43
  8. Kessing LV, 2004, J NEUROL NEUROSUR PS, V75, P1662, DOI 10.1136/jnnp.2003.031773
  9. Munkholm K, 2012, BIPOLAR DISORD, V14, P684, DOI 10.1111/bdi.12005
  10. Karege F, 2012, J AFFECT DISORDERS, V136, P185, DOI 10.1016/j.jad.2011.09.024
  11. Besing RC, 2015, J BIOL RHYTHM, V30, P155, DOI 10.1177/0748730415573167
  12. Munkholm K, 2015, BRAIN BEHAV IMMUN, V43, P205, DOI 10.1016/j.bbi.2014.09.021
  13. Sullivan PF, 2006, AM J MED GENET B, V141B, P261, DOI 10.1002/ajmg.b.30272
  14. Kessing LV, 1999, ACTA PSYCHIAT SCAND, V100, P176, DOI 10.1111/j.1600-0447.1999.tb10843.x
  15. Munkholm K, 2013, J PSYCHIATR RES, V47, P1119, DOI 10.1016/j.jpsychires.2013.05.018
  16. Munkholm K, 2014, PSYCHONEUROENDOCRINO, V47, P199, DOI 10.1016/j.psyneuen.2014.05.011
  17. Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2
  18. Gladkevich A, 2004, PROG NEURO-PSYCHOPH, V28, P559, DOI 10.1016/j.pnpbo.2004.01.009
  19. Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221
  20. Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
  21. Kapczinski F, 2008, NEUROSCI BIOBEHAV R, V32, P675, DOI 10.1016/j.neubiorev.2007.10.005
  22. Diniz BS, 2011, WORLD J BIOL PSYCHIA, V12, P216, DOI 10.3109/15622975.2010.551408
  23. Leonard B, 2012, NEUROSCI BIOBEHAV R, V36, P764, DOI 10.1016/j.neubiorev.2011.12.005
  24. Joaquim HPG, 2012, J PSYCHIATR RES, V46, P1053, DOI 10.1016/j.jpsychires.2012.04.020
  25. Karege F, 2007, BIOL PSYCHIAT, V61, P240, DOI 10.1016/j.biopsych.2006.04.036
  26. Pandey GN, 2010, J PSYCHIATR RES, V44, P143, DOI 10.1016/j.jpsychires.2009.07.009
  27. Kessing LV, 2011, BRIT J PSYCHIAT, V199, P57, DOI 10.1192/bjp.bp.110.084822
  28. Kim HW, 2011, MOL PSYCHIATR, V16, P419, DOI 10.1038/mp.2009.137
  29. WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
  30. Bazinet RP, 2006, BIOL PSYCHIAT, V59, P401, DOI 10.1016/j.biopsych.2005.07.024
  31. Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
  32. Kessing LV, 2008, ARCH GEN PSYCHIAT, V65, P1331, DOI 10.1001/archpsyc.65.11.1331
  33. Cheon Y, 2011, J NEUROCHEM, V119, P364, DOI 10.1111/j.1471-4159.2011.07410.x
  34. Hoehn KL, 2004, AM J PHYSIOL-REG I, V286, pR498, DOI 10.1152/ajpregu.00509.2003
  35. Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868
  36. Marksteiner J, 2009, EXP GERONTOL, V44, P370, DOI 10.1016/j.exger.2009.02.007
  37. Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
  38. Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08
  39. MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
  40. Hye A, 2005, NEUROSCI LETT, V373, P1, DOI 10.1016/j.neulet.2004.10.031
  41. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  42. Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
  43. Berk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001
  44. Petersen ML, 2006, EPIDEMIOLOGY, V17, P276, DOI 10.1097/01.ede.0000208475.99429.2d
  45. Li XH, 2010, BIPOLAR DISORD, V12, P741, DOI 10.1111/j.1399-5618.2010.00866.x
  46. Derogatis L, 1983, BRIEF SYMPTOM INVENT, V13, P595, DOI 10.1017/S0033291700048017
  47. Goldstein BI, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0425-9
  48. Kaladchibachi Sevag A, 2007, J Circadian Rhythms, V5, P3, DOI 10.1186/1740-3391-5-3
  49. King MK, 2014, PHARMACOL THERAPEUT, V141, P1, DOI 10.1016/j.pharmthera.2013.07.010
  50. Munkholm K, 2015, INT J NEUROPSYCHOPH, V18
  51. Peineau S, 2008, BRIT J PHARMACOL, V153, pS428, DOI 10.1038/bjp.2008.2
  52. Randolph C., 1998, RBANS MANUAL REPEATA
  53. Torres IJ, 2007, ACTA PSYCHIAT SCAND, V116, P17, DOI 10.1111/j.1600-0447.2007.01055.x
  54. War Department AGsO, 1944, ARM IND TEST BATT MA
  55. WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
  56. Wechsler D, 1997, WECHSLER ADULT INTEL
  57. WOODGETT JR, 1990, EMBO J, V9, P2431

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27